ERBB2 and breast carcinoma: The primary end point of NAT is pathological complete response (pCR); the prognosis of patients who achieve pathological complete response (pCR) was observed to be significantly better than that of non‐pCR patients Our analysis also sought to explore the potential impact of HR status on the survival outcomes of HER2‐positive breast cancer patients undergoing NAT.